CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 87 enrolled
Drug / intervention
Memantine +2 moredrug
Likely dose
Memantine 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01052662
NCT01052662Phase 3Completed
CompareCT.gov

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

University of Massachusetts, Worcester·interventional·Posted Jan 20, 2010·Updated Apr 1, 2015

In Brief

A Phase 3 clinical trial evaluating Memantine and Placebo for Opioid Dependence. Completed, enrolled 87 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the effect of memantine and buprenorphine on opioid abusing behavior, to determine the effect of memantine and buprenorphine on early relapse and to evaluate the tolerability of memantine co-administrated with buprenorphine. The study seeks to determine if combined treatment of memantine and buprenorphine may provide shorter-term treatment for opioid dependence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 20, 2010
Enrollment StartOct 1, 2009
Primary CompletionJun 1, 2013
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 16.4 years ago

Interventions

Memantinedrug

30mg/day Memantine orally everyday for 12 weeks

Memantinedrug

15 mg/day Memantine orally everyday for 12 weeks

Placebodrug

Placebo orally everyday for 12 weeks